Ozempic is being hailed as “the end of the Obesity Epidemic.” This week, Mike and Aubrey dig through the sensational claims. But will they make it past the caveats?

Links:

• How a Canadian scientist and a venomous lizard helped pave the way for Ozempic
• The Discovery and Development of Liraglutide and Semaglutide
• Ozempic and Wegovy maker courts prominent Black leaders to get Medicare's favor
• Insurers clamping down on doctors who prescribe Ozempic for weight loss
• Ozempic prescriptions can be easy to get online. Its popularity for weight loss is hurting those who need it most
• Glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: real-world evidence from a Mediterranean area
• Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity
• Real-world weight change, adherence, and discontinuation among patients with type 2 diabetes initiating glucagon-like peptide-1 receptor agonists in the UK
• Safety of Semaglutide
• Semaglutide for the treatment of overweight and obesity: A review
• Once-Weekly Semaglutide in Adolescents with Obesity
• Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5
• Association of Glucagon-Like Peptide-1 Receptor Agonist Use With Risk of Gallbladder and Biliary Diseases
• Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States
• Medications and conditions associated with weight loss in patients prescribed semaglutide based on real-world data

Thanks to Doctor Dreamchip for our lovely theme song!

Support the Show.